pioglitazone has been researched along with Glomerulosclerosis, Focal Segmental in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Glomerulosclerosis, Focal Segmental: A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS." | 8.31 | Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023) |
| "While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS." | 4.31 | Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hunley, TE | 1 |
| Hidalgo, G | 1 |
| Ng, KH | 1 |
| Shirai, Y | 1 |
| Miura, K | 1 |
| Beng, HM | 1 |
| Wu, Q | 1 |
| Hattori, M | 1 |
| Smoyer, WE | 1 |
| Sharma, A | 1 |
| Bourey, RE | 1 |
| Edwards, JC | 1 |
| Brink, DS | 1 |
| Albert, SG | 1 |
| Matsushita, K | 1 |
| Yang, HC | 1 |
| Mysore, MM | 1 |
| Zhong, J | 1 |
| Shyr, Y | 1 |
| Ma, LJ | 1 |
| Fogo, AB | 1 |
| Toblli, JE | 1 |
| Ferrini, MG | 1 |
| Cao, G | 1 |
| Vernet, D | 1 |
| Angerosa, M | 1 |
| Gonzalez-Cadavid, NF | 1 |
| Zhou, TB | 1 |
| Ou, C | 1 |
| Luo, CP | 1 |
| Xu, HL | 1 |
5 other studies available for pioglitazone and Glomerulosclerosis, Focal Segmental
| Article | Year |
|---|---|
Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome.
Topics: Child; Glomerulosclerosis, Focal Segmental; Humans; Nephrotic Syndrome; Pioglitazone; Proteinuria; S | 2023 |
Nephrotic range proteinuria associated with focal segmental glomerulosclerosis reversed with pioglitazone therapy in a patient with Dunnigan type lipodystrophy.
Topics: Adult; Female; Glomerulosclerosis, Focal Segmental; Humans; Hypoglycemic Agents; Kidney Diseases; Li | 2021 |
Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Blood Pressure; Creatinine; Diseas | 2016 |
Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus.
Topics: Animals; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Fibrosis; Glomerulosclerosis, Focal | 2009 |
Protective effects of PPARγ agonist in glomerulosclerosis rats induced by adriamycin.
Topics: Animals; Antibiotics, Antineoplastic; Doxorubicin; Glomerulosclerosis, Focal Segmental; Hypoglycemic | 2012 |